🟢 BioLineRx is trading 5% up on October 20, 2026, as biotech ETF XBI rises

BioLineRx is trading at $2.12, up 5.20%, amid broader biotech-sector strength, with XBI up 2.10% during the regular session.

• No new company-specific catalyst was identified; BioLineRx’s investor-relations page lists its latest release on October 8, about GLIX1 presentations at a November meeting.
• Wider biotech deal and clinical-trial news may support sentiment, but does not establish a BioLineRx-specific cause.